Market Size of Controlled Release Drug Delivery Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Controlled Release Drug Delivery Market Analysis
The controlled-release drug delivery market is projected to register a CAGR of 8% during the forecast period.
- The COVID-19 pandemic impacted the studied market growth since the majority of the market players were focusing on COVID-19 vaccine development, and there were manufacturing restrictions in pharmaceutical and biopharmaceutical plants due to lockdown restrictions in the initial phase of the pandemic. However, the later stage of the pandemic was associated with research activities employing the control release drug delivery for COVID-19.
- For instance, according to an article published in Elsevier Public Health Emergency Collection in January 2022, researchers were developing targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. Hence, owing to the above-mentioned factors, the market studied had a significant impact on the market studied. However, with the COVID-19 cases in control, the market is re-gaining its pre-pandemic nature in terms of demand for controlled-release drug delivery technologies for research and development.
- Furthermore, the rising prevalence of chronic diseases is expected to boost the demand for controlled-release drug delivery technology as it maximizes the efficacy of the therapeutic and minimizes the side effects, which adds to the market's growth.
- According to the American Cancer Society Cancer Statistics 2023, 1.9 million new cancer cases are predicted to be diagnosed in the United States in 2023. The high burden of cancer creates an opportunity for market players to develop innovative drugs that boost the utilization of controlled-release drug delivery technologies, which in turn expand the market growth.
- Additionally, according to 2022 statistics published by National Health Science, about 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2021, accounting for 1.9% of the total population. Also, as per the Australian Bureau of Statistics, updated in 2022, 375.8 thousand individuals (1.5%) of all ages had chronic obstructive pulmonary disease in 2021. The high burden of COPD worldwide boosts the demand for controlled-release drugs that can be used in various types of inhalers, which is projected to augment the market growth during the forecast period.
- Furthermore, the strategic initiatives by market players for innovation and launches in existing products also contribute significantly to market growth. For instance, in November 2021, AMW GmbH and AdhexPharma SAS entered into a strategic partnership for the expansion of AMW's transdermal delivery systems (TDS), combining the strengths of both companies.
- Also, in February 2022, AstraZeneca launched the Ambition Zero Carbon Program in partnership with Honeywell to develop next-generation respiratory inhalers. Under the partnership, the companies will eliminate the propellent that was earlier used in metered dose inhalers for patients with asthma and COPD. Therefore, the partnership will boost the development of advanced metered dose inhalers, which is further projected to accelerate the market growth during the forecast period.
- Therefore, factors such as the rising prevalence of chronic disease and increasing strategic initiatives by market players are expected to drive market growth during the forecast period. However, the higher cost compared to the conventional method is projected to restrain the market growth during the forecast period.
Controlled Release Drug Delivery Industry Segmentation
Controlled-release drug delivery is the dosage form that delivers a drug or medication in a predetermined manner. This drug delivery system provides continuous drug or medication delivery in predictable kinetics for the predetermined time in the whole course of gastrointestinal transit.
The controlled-release drug delivery market is segmented by technology (microencapsulation, transdermal, targeted delivery, and other technologies), application (metered dose inhalers, injectable, transdermal, ocular patches, and other applications), and geography (North America, Europe, Asia-pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally.
The report offers values (in USD) for the above segments.
| By Technology | |
| Micro Encapsulation | |
| Transdermal | |
| Targeted delivery | |
| Other Technologies |
| By Application | |
| Metered Dose Inhalers | |
| Injectable | |
| Transdermal and Ocular Patches | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Controlled Release Drug Delivery Market Size Summary
The controlled-release drug delivery market is experiencing a resurgence as it moves past the disruptions caused by the COVID-19 pandemic, which had initially diverted focus towards vaccine development and imposed manufacturing restrictions. The market is now benefiting from the increasing demand for controlled-release technologies in research and development, particularly in the context of chronic disease management. The rising prevalence of conditions such as cancer and chronic obstructive pulmonary disease (COPD) is driving the need for innovative drug delivery solutions that enhance therapeutic efficacy while minimizing side effects. Strategic initiatives by key market players, including partnerships and product launches, are further propelling market growth. These efforts are aimed at developing advanced drug delivery systems, such as transdermal and inhaler technologies, which are expected to expand the market's reach and application.
The targeted drug delivery segment is poised for significant growth due to its ability to provide prolonged therapeutic effects and its increasing demand among geriatric and pediatric populations. Innovations in this area, such as the development of antibody-drug conjugates, are expected to dominate the market. North America is anticipated to hold a substantial market share, driven by the high incidence of chronic diseases and proactive product launches. The region's market growth is supported by collaborations and technological advancements in transdermal delivery systems. The competitive landscape is characterized by the presence of major players like Adare Pharma Solutions and Merck & Co., Inc., who are actively engaging in research and development to meet the evolving demands of the market.
Controlled Release Drug Delivery Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Incidence of Chronic diseases
-
1.2.2 Growing Geriatric and Pediatric Population
-
-
1.3 Market Restraints
-
1.3.1 Higher Cost Compared to the Conventional Method
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Technology
-
2.1.1 Micro Encapsulation
-
2.1.2 Transdermal
-
2.1.3 Targeted delivery
-
2.1.4 Other Technologies
-
-
2.2 By Application
-
2.2.1 Metered Dose Inhalers
-
2.2.2 Injectable
-
2.2.3 Transdermal and Ocular Patches
-
2.2.4 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Controlled Release Drug Delivery Market Size FAQs
What is the current Global Controlled Release Drug Delivery Market size?
The Global Controlled Release Drug Delivery Market is projected to register a CAGR of 8% during the forecast period (2024-2029)
Who are the key players in Global Controlled Release Drug Delivery Market?
Adare Pharma Solutions, Merck KGaA, Johnson and Johnson, Lonza Group AG (Capsugel) and Colorcon are the major companies operating in the Global Controlled Release Drug Delivery Market.
